X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dr. Reddy’s: Positive news flow continues - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jul 20, 2001

    Dr. Reddy’s: Positive news flow continues

    Dr. Reddy's case for marketing fluoxetine (Prozac) 40 mg capsules has moved in the right direction. The U.S. appeals court has rejected the original patent holders case for rehearing regarding Prozac. Meanwhile Dr. Reddy’s was also successful in tying up the final outcome of its litigation with that of Barr Labs.

    It may be recalled that Barr Labs has ANDA for launching 10/20 mg fluoxetine and it recently won the litigation against Eli Lilly, the original patent holder of the drug for marketing the same with six months exclusivity. While Barr case was for 10 mg / 20 mg exclusivity, Dr. Reddy’s had a similar case (for the same drug) for 40 mg dosage.

    It now effectively means that Dr. Reddy would be able to market 40 mg fluoxetine capsules with six-month exclusivity. It would be first time that an Indian company would market a drug with marketing exclusivity. The potential for Dr. Reddy’s is huge given the fact that the annual branded sales for fluoxetine are in the range of US $ 275 m. It is expected that fluoxetine sales would add an incremental net profit of US $ 16-17 m for the company. Dr. Reddy’s recorded a net profit of US $ 28 m for FY01.

    In another positive development, Novartis and Novo Nordisk announced an agreement on the commercialization of the company’s diabetes molecule (DRF 2725 which is out licensed to Novo Nordisk). This agreement entitles Novartis exclusive marketing rights for US, Canada and Mexico while Novo Nordisk would continue to be responsible for the development and global regulatory approval. This agreement reinforces Novo Nordisk’s confidence in the molecule and priority it is attaching to it. The royalty payment to Dr. Reddy’s that would be spread over the commercial life of the molecule (if Novo Nordisk is successful to get it to market) could be eye popping.

    At the current market price of Rs 1665, the stock is trading at 47x FY01 earnings. Dr. Reddy’s strong research and ANDA pipeline is capable of giving further such pleasant surprises in future. Further, ADR funds deployment for in-organic growth could be another trigger for the stock in coming weeks. Dr. Reddy’s plans to acquire a marketing company in the US. However, we reiterate that at the current valuations, markets have built in a lot of expectations from the company. Internationally, pharma companies see drastic fall in valuations on failure of molecules, as the markets tend to discount the gains ahead of the launch. The flip side thus for Dr. Reddy’s is any negative development could trigger a steep fall in valuations.

     

     

    Equitymaster requests your view! Post a comment on "Dr. Reddy’s: Positive news flow continues". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    MARKET STATS